Experimental HCV Drugs
Experimental HCV Drugs
EASL 2011: First Sustained Response Data for HCV Polymerase Inhibitor Mericitabine
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 05 April 2011 14:14
- Written by Liz Highleyman
76% of treatment-naive genotype 1 or 4 hepatitis C patients achieved 12-week sustained response to mericitabine (formerly RG7128) plus pegylated interferon/ribavirin, according to a report at EASL 2011. 
EASL 2011: Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 05 April 2011 08:05
- Written by Liz Highleyman
Almost all treatment-naive hepatitis C patients treated with Pharmasset's candidate PSI-7977 plus pegylated interferon/ribavirin experienced 12-week sustained response, and more than 90% treated with a PSI-7977 + PSI-938 all-oral combo had undetectable HCV at 14 days, researchers reported at EASL. 
HCV Polymerase Inhibitor INX-189 Gets FDA Fast-Track Status, TMC649128 Enters Phase 1a Trial
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 07 March 2011 21:01
- Written by Liz Highleyman
The development of direct-acting antiviral agents active against hepatitis C virus (HCV) continues at a rapid pace. Two pharmaceutical companies this month announced progress in the development of investigational HCV polymerase inhibitors. Inhibitex said that it's candidate INX-189 has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA), which allows for accelerated review and approval. Sweden's Medivir announced the start of the first human trial of its drug, TMC649128, in healthy volunteers.
CROI 2011: HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and Non-responders
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 15 March 2011 12:37
- Written by Liz Highleyman
Merck's investigational hepatitis C virus (HCV) protease inhibitor boceprevir improved sustained response rates when combined with pegylated interferon plus ribavirin in both previously untreated patients and those who were non-responders or relapsers after prior therapy, according to 2 Phase 3 studies presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) this month in Boston. 
Anadys Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 01 February 2011 12:41
- Written by Anadys
Anadys Pharmaceuticals announced this week that it has begun treating the first participants in a Phase 2b clinical trial of its investigational hepatitis C virus (HCV) polymerase inhibitor ANA598. The new drug will be tested in combination with pegylated interferon plus ribavirin in both previously untreated patients and people who did not achieve sustained response to prior therapy.
More Articles...
- FDA Suspends Trials of Experimental HCV Regimen IDX184 plus IDX320 Due to Liver Toxicity Concerns
- Addition of HCV Protease Inhibitor Telaprevir Can Shorten Interferon-based Treatment
- EASL 2010: Achillion Announces Additional Promising Data from Phase 1b Trial of HCV Protease Inhibitor ACH-1625
- HCV Polymerase Inhibitor IDX184, Protease Inhibitor IDX320 and Triple Combination Show Promising Antiviral Activity
Web Design and Development by